Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents

2020-06-29T15:20:07+01:00

Remain vigilant for signs and symptoms of bleeding complications during treatment with DOACs (apixaban, dabigatran, edoxaban, rivaroxaban), especially in patients with increased bleeding risks. Specific reversal agents are a…